|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-1
|
|
pubmed:abstractText |
Recently, gene amplification and overexpression of KIT as well as activating mutations in the KIT gene have been described to occur in certain subsets of melanoma. These findings suggest KIT as a potential target for therapy with imatinib mesylate in these melanomas. To date, data on the KIT status in uveal melanoma (UM) is limited.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
324-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19118061-Aged,
pubmed-meshheading:19118061-Aged, 80 and over,
pubmed-meshheading:19118061-Female,
pubmed-meshheading:19118061-Humans,
pubmed-meshheading:19118061-Male,
pubmed-meshheading:19118061-Melanoma,
pubmed-meshheading:19118061-Middle Aged,
pubmed-meshheading:19118061-Mutation,
pubmed-meshheading:19118061-Piperazines,
pubmed-meshheading:19118061-Protein-Tyrosine Kinases,
pubmed-meshheading:19118061-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:19118061-Pyrimidines,
pubmed-meshheading:19118061-Stem Cell Factor,
pubmed-meshheading:19118061-Up-Regulation,
pubmed-meshheading:19118061-Uveal Neoplasms
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
|
|
pubmed:affiliation |
Department of Dermatology, Julius Maximilians University, Würzburg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
